Roche's Cobas EGFR Assay Gets CE Mark | GenomeWeb

NEW YORK (GenomeWeb) – Roche today announced that the Cobas EGFR Mutation Test v2 has received CE marking and is commercially available in countries that accept the designation. 

The test is Roche's first that uses either plasma or tissue as a sample type, the firm said. It identifies 42 mutations in the epidermal growth factor receptor gene and can be used to help select patients with non-small lung cancer for treatment with an EGRF tyrosine kinase inhibitor. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Sponsored by

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.